The Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment
Open accessThe DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Abstract
Gut microbiota is emerging as a key regulator of many disease conditions and its dysregulation is implicated in the pathogenesis of several gastrointestinal and extraintestinal disorders. More recently, gut microbiome alterations have been linked to neurodegeneration through the increasingly defined gut microbiota brain axis, opening the possibility for new microbiota-based therapeutic options. Although several studies have been conducted to unravel the possible relationship between Alzheimer’s Disease (AD) pathogenesis and progression, the diagnostic and therapeutic potential of approaches aiming at restoring gut microbiota eubiosis remain to be fully addressed. In this narrative review, we briefly summarize the role of gut microbiota homeostasis in brain health and disease, and we present evidence for its dysregulation in AD patients. Based on these observations, we then discuss how dysbiosis might be exploited as a new diagnostic tool in early and advanced disease stages, and we examine the potential of prebiotics, probiotics, fecal microbiota transplantation, and diets as complementary therapeutic interventions on disease pathogenesis and progression, thus offering new insights into the diagnosis and treatment of this devastating and progressive disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the successful use of FMT in the treatment of refractory or recurrent Clostridium difficile infection, several studies have been conducted to explore FMT as a therapeutic strategy for a wide range of neurological disorders, including multiple sclerosis, epilepsy, ASD, Tourette syndrome, diabetic neuropathy, AD and PD, with promising preclinical and clinical data [30,465,466,467,468].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“GM-based biomarkers have recently been considered as promising early and prodromal diagnostic tools in various neurological diseases, such as multiple sclerosis, AD and PD itself [30,156,157]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Bravo, J. A., Forsythe, P., Chew, M. V., Escaravage, E., Savignac, H. M., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102999108 · Cited by 3,888 · cited 1×
“• Through incoming and outgoing branches of the vagus nerve [26], which represents the major modulatory pathway [27].”
BackgroundParada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00277 · Cited by 3,820 · cited 1×
“As mentioned, another beneficial role exerted by the gut microbiota is the production of SCFAs, including butyrate, propionate, and acetate, essential for energy production, gut epithelia homeostasis, and immune regulation [83].”
BackgroundFormation of short chain fatty acids by the gut microbiota and their impact on human metabolism
Morrison, D. J., & Preston, T. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1134082 · Cited by 3,781
Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., & Mele, M. C. (2019) · Microorganisms · doi:10.3390/microorganisms7010014 · Cited by 3,462 · cited 1×
“Although the composition of a “healthy microbiota” has not yet been defined, a balanced environment between the host and microorganisms is known to be essential to carry on the necessary immunological and metabolic functions [58].”
BackgroundPathophysiology of type 2 diabetes mellitus
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176275 · Cited by 3,360
Normal gut microbiota modulates brain development and behavior
Heijtz, R. D., Wang, S., Anuar, F., Qian, Y., Björkholm, B., Samuelsson, A., Hibberd, M. L., Forssberg, H., & Pettersson, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010529108 · Cited by 3,228 · cited 1×
“This alteration, in turn, may affect the CNS through the modulation of stress hormones [28].”
Background
Cited by
Items 101–200 of 239
Food for the mind: The journey of probiotics from foods to anti-Alzheimer’s disease therapeutics
Anand, A., Khurana, N., Kumar, R., & Sharma, N. (2022) · Food Bioscience · doi:10.1016/j.fbio.2022.102323 · Cited by 13
Current Diagnostic and Treatment Methods of Alzheimer’s Disease: A Narrative Review
Dafre, R., & Wasnik, P. (2023) · Cureus · doi:10.7759/cureus.45649 · Cited by 13
The role of nutrition in mild traumatic brain injury rehabilitation for service members and veterans
Monti, K. S., Conkright, M. W., Eagle, S. R., Lawrence, D. W., & Dretsch, L. M. (2024) · Neurorehabilitation · doi:10.3233/nre-230241 · Cited by 13
Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer’s Disease
Li, H., Shen, X., Zhang, B., & Zhu, Z. (2025) · Molecules · doi:10.3390/molecules30173479 · Cited by 12
“…provide compelling evidence that transplantation of microbiota from AD patients into germ-free mice can accelerate amyloid accumulation and cognitive deficits, while probiotic supplementation has been shown to improve memory performance and synaptic plasticity in transgenic AD models [104,105].”
Solberg, B. S., Kvalvik, L. G., Instanes, J. T., Hartman, C. A., Klungsøyr, K., Li, L., Larsson, H., Magnus, P. M., Njølstad, P. R., Johansson, S., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.12.017 · Cited by 12
Review on pathogenesis and treatment of Alzheimer's disease
Cai, J., Liu, Y., & Fan, H. (2024) · Developmental Dynamics · doi:10.1002/dvdy.762 · Cited by 11
Chen, J., Yin, X., He, H., Lu, L. W., Wang, M., Liu, B., & Cheng, K. (2024) · Food & Function · doi:10.1039/d3fo03805j · Cited by 11
Linking gut microbiota dysbiosis to molecular pathways in Alzheimer’s disease
Asadifard, E., Hokmabadi, M., Hashemi, M., & Bereimipour, A. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149242 · Cited by 10
Gut microbiota as a potential therapeutic target for children with cerebral palsy and epilepsy
Wu, H., Huang, C., & Xiong, S. (2024) · Brain and Development · doi:10.1016/j.braindev.2024.09.002 · Cited by 9
“Studies [31] have found that AD patients exhibit significant dysbiosis of GM, reduced gut microbial diversity, and a decrease in the abundance of Firmicutes .”
BackgroundEmerging mechanisms of organ crosstalk: The role of oxylipins
Fisk, H. L., & Shaikh, S. R. (2024) · Nutrition Bulletin · doi:10.1111/nbu.12726 · Cited by 11
Yang, F., Yan, Q., Wang, Y., Li, Q., Wang, J., Zeng, X., Pi, Y., Zhang, M., & Wei, L. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156447 · Cited by 9
Alzheimer’s: Epidemiology, Pathophysiology, Diagnosis, and Treatments
Rahman, A. T. F., Jaiswal, A., Keshari, P., & Singh, D. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-6202-9_2 · Cited by 12
Oso, T. A., Ahmed, M. M., Okesanya, O. J., Adebayo, U. O., Obadeyi, K. B., Othman, Z. K., & Lucero‐Prisno, D. E. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251407700 · Cited by 9
“31 These microbial shifts are often associated with increased gut permeability, systemic in fl ammation, and neuroin fl ammatory cascades that precede the cognitive decline.”
Alzheimer’s Disease: Understanding Its Novel Drug Delivery Systems and Treatments
Dhingra, H., & Choudhari, S. G. (2022) · Cureus · doi:10.7759/cureus.31394 · Cited by 9
“The glymphatic system deals with the circulation, buildup, and clearance mechanisms of metabolic waste [36].”
BackgroundEffects of Probiotics on Colitis-Induced Exacerbation of Alzheimer’s Disease in AppNL-G-F Mice
Sahu, B., Johnson, L. M., Sohrabi, M., Usatii, A. A., Craig, R. M. J., Kaelberer, J. B., Chandrasekaran, S. P., Kaur, H., Nookala, S., & Combs, C. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411551 · Cited by 10
Bernardes, L. M. M., Malta, S. M., Rodrigues, T. S., Covizzi, L. F., Rosa, R. B., Justino, A. B., Teixeira, R. R., Espíndola, F. S., dos Santos, D. O., Ueira‐Vieira, C., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291242 · Cited by 12
Banerjee, A., Mal, S., Roy, P., & Chatterji, U. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118250 · Cited by 10
Sait, A. M., & Day, P. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168619 · Cited by 9
“The use of prebiotics and probiotics is known as synbiotics, and it has been demonstrated to be effective in AD animal models [10].”
BackgroundEther Derivatives of Naringenin and Their Oximes as Factors Modulating Bacterial Adhesion
Duda-Madej, A., Kozłowska, J., Baczyńska, D., & Krzyżek, P. (2023) · Antibiotics · doi:10.3390/antibiotics12061076 · Cited by 8
“In that respect, of particular interest are reports highlighting the involvement of intestinal bacteria in the development of some severe neurodegenerative conditions, such as Parkinson’s and Alzheimer’s disease [12,13].”
BackgroundViruses - a major cause of amyloid deposition in the brain
Fülöp, T., Ramassamy, C., Lévesque, S., Frost, E. H., Laurent, B., Lacombe, G., Khalil, A., Larbi, A., Hirokawa, K., Desroches, M., et al. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2244162 · Cited by 8
An Overview of Gastrointestinal Dysfunction in Parkinsonian Syndromes
Talman, L. S., & Safarpour, D. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771461 · Cited by 8
Yan, L., Li, H., Qian, Y., Liu, Q., Cong, S., Dou, B., Wang, Y., Wang, M., & Yu, T. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1334735 · Cited by 10
Ismeurt, C., Giannoni, P., Servant, F., Mekki, L.-N., Baranger, K., Rivera, S., Marin, P., Lelouvier, B., & Claeysen, S. (2025) · mBio · doi:10.1128/mbio.04001-24 · Cited by 7
Kaur, S., Kumari, D., & Dandekar, M. P. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04685-5 · Cited by 7
“Thus, the identification of specific biomarkers of AD requires more studies [5].”
Deciphering T Cell Dynamics in Alzheimer's Disease Pathogenesis: Insights and Implications
Yang, Q., Qiu, Y., Ni, J., Li, H., & Qing, H. (2025) · Current Neuropharmacology · doi:10.2174/011570159x350611250303044527 · Cited by 7
Wang, R., Li, J., Li, X., Guo, Y., Chen, P., & Tian, P. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0013 · Cited by 7
Implications of the Gut Microbiome in Alzheimer’s Disease: A Narrative Review
Mroke, P., Goit, R., Rizwan, M., Tariq, S., Rizwan, A. W., Umer, M., Nassar, F. F., Sarria, A. J. T., Singh, D., & Baig, I. (2024) · Cureus · doi:10.7759/cureus.73681 · Cited by 9
Vera, D. M., López-Gambero, A. J., Verheul-Campos, J., Navarro, J. A., Morelli, L., Galeano, P., Suárez, J., Sanjuan, C., Pacheco-Sánchez, B., Rivera, P., et al. (2024) · Nutrients · doi:10.3390/nu16234186 · Cited by 8
Age-driven dysbiosis: gut microbiota in the pathogenesis and treatment of aging disorders
Kopalli, S. R., Wankhede, N. L., Rahangdale, S. R., Sammeta, S. S., Aglawe, M. M., Koppula, S., Taksande, B. G., Upaganlawar, A., Umekar, M. J., & Kale, M. B. (2026) · Biogerontology · doi:10.1007/s10522-026-10389-1 · Cited by 7
“(2026) 27:42 Page 25 of 29 42”
Consales, A., Toscano, L., Ceriotti, C., Tiraferri, V., Castaldi, S., & Giannì, M. L. (2024) · BMC Public Health · doi:10.1186/s12889-024-18497-8 · Cited by 8
“…alterations in the composition and variability of the human microbiota can contribute to the development of various pathological conditions, ranging from immunological [15–18] to gastrointestinal [19, 20], metabolic [20–22], neurodevelopmental [23], neurological [24] and psychiatric [25] diseases.”
BackgroundHou, B.-Y., Wu, M.-H., Hsu, H.-Y., Lin, Y., & Yang, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137316 · Cited by 6
Wang, W., Zhang, J., & Li, C. (2024) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174241290962 · Cited by 6
“5 Compared to healthy individuals, patients with AD exhibit altered gut microbiota compositions.”
Chen, Y., Peng, Y., Niu, Q., Jiang, Y., Ni, H., Chen, L., & Lin, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177326 · Cited by 9
Gut Microbiome Transplants and Their Health Impacts across Species
Levine, B. H., & Hoffman, J. M. (2023) · Microorganisms · doi:10.3390/microorganisms11061488 · Cited by 7
Does a pickle a day keep Alzheimer's away? Fermented food in Alzheimer's disease: A review
Tyliszczak, M., Wiatrak, B., Danielewski, M., Szeląg, A., Kucharska, A. Z., & Sozański, T. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112332 · Cited by 8
An Update on Neuroaging on Earth and in Spaceflight
Kuznetsov, N. V., Statsenko, Y. A., & Ljubisavljević, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041738 · Cited by 7
Muronets, V. I., Kudryavtseva, S. S., Kurochkina, L. P., Leisi, E. V., Stroylova, Y. Y., & Schmalhausen, E. V. (2025) · Biochemistry (Moscow) · doi:10.1134/s0006297924604003 · Cited by 5
“Several reviews on this topic state that patients with AD have dysbiosis [243].”
Gut Microbiota and Alzheimer Disease
Huarcaya, L. R. D. (2025) · Acta Neurologica Taiwanica · doi:10.4103/ant.ant_113_0046 · Cited by 5
Alzheimer’s disease: where do we stand now and what are the strategic interventions?
González, A., Geywitz, S., & Maccioni, R. B. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1655342 · Cited by 5
“…diabetes (González et al., 2022a); (ii) Gut-brain axis and commensal bacteria: several studies sustain that AD patients suer changes in the intestinal microbiota, promoting pro-inflammatory signals that reach the brain and trigger pro-inflammatory signals (Jiang et al., 2017; Varesi et al., 2022).”
Chowdhury, M., Chaudhary, N. R., Kaur, P., Goyal, A., & Sahu, S. K. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265267536231121095634 · Cited by 7
Glinert, A., Zlidennyy, V., Turjeman, S., Sharon, E., Schweitzer, R., Khatib, S., Izakson, L., & Koren, O. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116196 · Cited by 5
Dietary sugar intake, genetic susceptibility, and risk of dementia: A prospective cohort study
An, Y., Cao, L., Zheng, G., Liu, Y., Yang, H., Chen, L., Zhao, Y., Zhang, X., & Xia, Y. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100312 · Cited by 6
“…roles in physiological homeostasis and metabolism, promoting the development of the immune system, vitamin production, and nutrient absorption, and have been demonstrated to be involved in the onset of neurodegenerative diseases (such as glucose and fat metabolism and insulin sensitivity) [15,16].”
MicroSTNet: a spatio-temporal graph-based framework for time-series microbiome analysis
Gao, S., Li, L., Wang, J., Wang, Y., & Dong, Y. (2025) · Microbial Genomics · doi:10.1099/mgen.0.001519 · Cited by 7
“For example, the gut microbiome has been implicated in diagnosing and potentially treating Alzheimer’s disease [5].”
Influence of the Gut Microbiota on the Pathogenesis of Alzheimer’s Disease: A Literature Review
Batko, J., Antosz, K., Suchecki, W., Szyller, H. P., Wrześniewska, M., Dyda, M., & Leszek, J. (2025) · Cells · doi:10.3390/cells14201578 · Cited by 5
“Studies also found that individuals with AD have lower microbial diversity, and in their gut microbiota, there is a predominance of butyrate-producing bacteria over lactate-producing bacteria [76] [Table 4].”
Cronin, B., Kandel, S., McElroy, T., Syed, S., Swinton, C., Corley, C., Sridharan, V., Robeson, M. S., & Allen, A. R. (2026) · Scientific Reports · doi:10.1038/s41598-025-33903-w · Cited by 4
Adhikary, K., Sarkar, R., Chowdhury, S. R., & Banerjee, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00031-0 · Cited by 4
Biswal, B., Satapathy, B. S., Maharana, L., & Pattnaik, S. (2025) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2025.2488455 · Cited by 4
“[122] In fact, changes in the composition of the gut microbiota cause the gut barrier to become more permeable and the immune system to become activated, which can lead to systemic inflammation.”
Ghosson, A., Soufan, F., Kaddoura, H., Fares, E., & Uwishema, O. (2025) · Health Science Reports · doi:10.1002/hsr2.70975 · Cited by 4
“This heightened cortisol can alter gut microbiota composition, which may further influence AD pathology through the gut – brain axis [74].”
Li, X., Qin, H., & Li, T. (2022) · Ibrain · doi:10.1002/ibra.12065 · Cited by 5
Looking at the periphery—new hypothesis to look for new targets for Alzheimer’s disease therapy
Ávila, J., Pérez, M., Ávila‐Villanueva, M., Santa‐María, I., & Hernández, F. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00044 · Cited by 4
Torraville, S. E., Flynn, C. M., Kendall, T. L., & Yuan, Q. (2023) · Biomedicines · doi:10.3390/biomedicines11071884 · Cited by 4
“Increased barrier permeability, as seen in AD studies, provides an opportunity for toxic amyloids, neuroinflammatory cytokines, lipopolysaccharides (LPS), and short-chain fatty acids (SCFAs) to move into the brain and seed neurodegeneration [38].”
BackgroundRen, X. Y., Wen, Y., Li, C., Yuan, M., Zhang, J., Li, S., Zhang, X., Wang, L., & Wang, S. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.105485 · Cited by 4
The role of Gut-Microbiome-Brain-axis in Alzheirmer's disease
Rocha, V. M. N., Rocha, V. M. N., Gomes, G. F., Galvão, S. L., de Paula, L. Z. M., Oliveira, M. E., Oliveira, I. D., da Silva, L. A., Freitas, V. H. M., Sales, C. R., et al. (2024) · Brazilian Journal of Clinical Medicine and Review · doi:10.52600/2965-0968.bjcmr.2023.2.3.22-28 · Cited by 3
“Prebiotics are studied as a tool for microbiota homeostasis. are non-digestible substances capable of stimulating the growth of certain bacteria, making it possible to direct the microbiome towards a pro-inflammatory or anti-inflammatory state [6].”
BackgroundInfluentialSip, S., Stasiłowicz-Krzemień, A., Sip, A., Szulc, P. M., Neumann, M., Kryszak, A., & Cielecka‐Piontek, J. (2024) · Molecules · doi:10.3390/molecules29153574 · Cited by 3
“In the context of Alzheimer’s disease, studies indicate a shift in gut microbiota composition, characterised by a decrease in beneficial bacterial species and an increase in pro-inflammatory bacteria [1–3].”
BackgroundRecent Insights on the Prospective role of Phytocompounds in Modulating Gut-Brain Axis
Kumari, N., Anand, S., Shah, K., & Chauhan, N. S. (2024) · Current Pharmacology Reports · doi:10.1007/s40495-024-00364-0 · Cited by 3
“Studies carried out by Cattaneo et al. demonstrated that that the microbiota of AD patients exhibits augmented pro-inflammatory endobacteria spe - cies of Escherichia / Shigella and reduced anti-inflammatory taxon E. rectale [137].”
High-amylose diet ameliorates LPS-induced cognitive impairment and depression-like phenotype
Takura, K., Wei, R., Takayanagi, R., Sakai, Y., Hattori, M., & Ohshima, T. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138295 · Cited by 3
“…gut microbiota to modulate neuroinflammation and CNS functions, the potential therapeutic effects of prebiotics, non-digestible substances that nourish beneficial bacteria, on cognitive impairment and depression have been widely demonstrated in both animal models and clinical research [29,30,31].”
Nabizadeh, A., Rafati, A., Karbalaei, N., Namavar, M. R., Hosseinzadeh, S., Jahromi, H. M., Rahimi, A., & Naseh, M. (2025) · Brain Structure and Function · doi:10.1007/s00429-025-03003-6 · Cited by 3
“Based on these insights, modulation of the gut microbi - ome through dietary and lifestyle improvements has been demonstrated to affect Aβ aggregation, decrease neuroin-flammation, and potentially slow disease progression (Varesi et al. 2022; Loh et al. 2024).”
Banerjee, A., Goswami, A., & Choudhury, A. (2025) · BioNanoScience · doi:10.1007/s12668-025-02276-9 · Cited by 3
“Alterations in gut microbial composition have been observed in various neuropsychiatric conditions, including PD [ 225] and AD [ 201 ].”
Rapaka, D., Saniotis, A., Monkgogi, T., & Bitra, V. R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.118999 · Cited by 3
TUDCA Ameliorates Cognitive Impairment in APP/PS1 Mice by Modulating the Microbiota–Gut–Brain Axis
Zhan, M., Chen, H., Fu, X., Tang, S., Song, X., Li, H., Zhu, L., & Wang, B. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48010087 · Cited by 5
Climate change, gut microbiome, and epilepsy—New paradigms beyond the gut-brain axis
Santangelo, A., Corsello, A., Villano, G., Diana, M. C., & Striano, P. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1726561 · Cited by 3
Oso, T. A., Okesanya, O. J., Adebayo, U. O., Obadeyi, K. B., Ayelaagbe, O. B., Talabi, O. A., Adewole, P. D., Anorue, C. O., Ahmed, M. M., Talabi, O., et al. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261436287 · Cited by 4
Muronetz, V. I., Kurochkina, L. P., Leisi, E. V., & Kudryavtseva, S. S. (2023) · Microbiology Research · doi:10.3390/microbiolres14040131 · Cited by 3
“Several reviews devoted to this problem have declared that Alzheimer’s patients have a deregulated microbiota [1] and that gut microbial metabolites, such as pro-inflammatory factors and short-chain fatty acids, could affect the pathogenesis of AD due to synaptic dysfunction and neuroinflammation,…”
Lactobacilli Probiotics Prevent Amyloid-Beta Fibril Formation In Vitro
Harrass, S., Quansah, M., Kumar, S., Radzieta, M., Jayawardena, B. M., Jones, C. E., David, M. A., Heng, B., Elbourne, L. D. H., Amanquah, S. D., et al. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10776-z · Cited by 3
Variation in Group Composition Alters an Early-Stage Social Phenotype in hAPP-Transgenic J20 Mice
Lanooij, S. D., Eisel, U. L. M., van der Zee, E. A., & Kas, M. J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221126 · Cited by 3
The Brain-Gut Axis in Alzheimer’s Disease
Patel, M. (2023) · Advances in Alzheimer s Disease · doi:10.4236/aad.2023.123003 · Cited by 3
Biocenosis of the vagina. Norm. Disruption. Restoration
Radzinskiy, V. E., Savicheva, A. M., Vorob'ev, S., Владимировна, С. Е., Shalepo, K. V., Budilovskaya, O. V., Husnutdinova, T., Krysanova, A. А., Guschin, A. E., Raevskaya, O., et al. (2023) · Publishing Center RIOR eBooks · doi:10.29039/978-5-907218-72-7 · Cited by 3
The Role of the Gut Microbiome in Neurological Diseases
Turner, T.-A. J., & Mangalam, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00103-2 · Cited by 3
Lou, Y., Chen, X., Zhao, L., Xuc, N., Zhang, L., Hu, W., & Qiu, Y. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1378959 · Cited by 3
“AD has recently been treated and prevented by regulating intestinal flora (65).”
BackgroundDifferential Patterns of Gut and Oral Microbiomes in Hispanic Individuals with Cognitive Impairment
Wadop, Y. N., Vasquez, E. L., Mathews, J. J., Muhammad, J. A. S., Pirela, R. V., Satizábal, C. L., Gonzales, M. M., Tanner, J. A., Maestre, G. E., Fonteh, A. N., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13102350 · Cited by 3
Grabrucker, S., Marizzoni, M., Silajdžić, E., Lopizzo, N., Mombelli, E., Nicolas, S., Dohm-Hansen, S., Scassellati, C., Moretti, D. V., Rosa, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.04.515189 · Cited by 3
Han, X., Meng, X., Wu, Y., Xia, W., Xue, S., Liu, X., Lyu, C., Li, Z., Yan, X., Jung, H. W., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1644847 · Cited by 2
“…three possible pathological mechanisms have been con fi rmed for AD, namely, amyloid-β (A β ) plaques (Ishii et al., 2024), tau hyperphosphorylation, leading to the formation of intracellular neuro fi brillary tangles (Varesi et al., 2022), and the loss of neuronal function (Park et al., 2025).”
Cheng, W., Zhang, Z., Liu, X., Jin, X., Li, Y., Zeng, Q., Qian, D. B., Ye, F., & Li, Q. (2025) · Spectrochimica Acta Part B Atomic Spectroscopy · doi:10.1016/j.sab.2025.107372 · Cited by 2
Multi‐modal machine learning and gut microbiome pathway analysis for Alzheimer's risk prediction
Jabeen, T., Karimi, F., Zomorrodi, A. R., & Khalilpour, K. R. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70340 · Cited by 2
Liu, C., Zhu, Z., Lin, H., Bush, W. S., Jenq, R. R., Cominelli, F., Pillai, J. A., Haines, J. L., Zhu, X., Xu, R., et al. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1735332 · Cited by 2
Ziaka, M. (2026) · Pathogens · doi:10.3390/pathogens15070659 · Cited by 2
“This imbalance leads to local inflammation, greater GI permeability, and compromised blood-brain barrier (BBB) function, ultimately fostering neuroinflammation (Figure 1) [58,59].”
Inflammatory Bowel Disease and Gut Microbiota Dysbiosis: Current understanding and Future Direction
Verma, R., Shiva, K., Singh, R., Sherawat, K., Simran, S., & Bhardwaj, P. (2024) · Journal of Biomedical and Pharmaceutical Research · doi:10.32553/jbpr.v13i1.1043 · Cited by 2
The Gut Microbiome and the Central Nervous System (CNS)
Vijay, A., Ahmad, F., Sudesh, R., & Balakrishnan, A. (2024) · Springer eBooks · doi:10.1007/978-981-99-8803-7_3 · Cited by 2
The Role of Gastrointestinal Dysbiosis and Fecal Transplantation in Various Neurocognitive Disorders
Castro-Vidal, Z. A., Mathew, F., Ibrahim, A. A., Shubhangi, F., Cherian, R., Choi, H. K., Begum, A., Ravula, H. K., & Giri, H. (2024) · Cureus · doi:10.7759/cureus.72451 · Cited by 5
Gut Microbiota’s role in lipoma development: evidence from mendelian randomization
Li, Y., Chen, J., Yao, H., Xu, X., Zheng, X., Wang, Y., & Wang, W. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1430671 · Cited by 2
“Compelling evidence suggests that the GM plays a role in the regulation of metabolic disorders, psychiatric conditions, and cancers, including gout (Tong et al., 2022), Alzheimer ’ s disease (Varesi et al., 2022), and lymphoma (Ml and Rh, 2014).”
Neurodegeneration: A Tale of Microbes and Neurons
Ioghen, O. C., Ioghen, M. R., & Popescu, B. O. (2025) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2025.32.1.7 · Cited by 2
Castelo-Martínez, L., Mallah, N. E. Z., Cavenaghi, A., Navarro, L., Martinón‐Torres, F., Gómez‐Carballa, A., & Salas, A. (2025) · medRxiv · doi:10.1101/2025.07.29.25332408 · Cited by 3
“As such, targeting the gut microbiome has been proposed as a promising strategy for preventing or modulating the progression of neurodegenerative diseases [58].”
Current Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets
Ranjan, A., Shukla, S., & Singh, S. (2024) · Current Drug Therapy · doi:10.2174/0115748855307998240529063710 · Cited by 1
Prediction of Crohn's disease based on deep feature recognition
Tian, H., & Tang, R. (2024) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2024.108231 · Cited by 1
Unveiling the Potential of Gut Microbiota: Promising Approaches to Treat Drug-Resistant Epilepsy
Domańska, N. A., Bojarska, M. K., Bogucka, J., Brzyska, A., Kosowska, M., & Piecewicz‐Szczęsna, H. (2024) · Quality in Sport · doi:10.12775/qs.2024.26.55121 · Cited by 1
“The CNS regulates the function and integrity of the gastrointestinal tract through the HPA neuroendocrine axis, inflammatory and immune pathways and the autonomic nervous system. and promotes the differentiation of helper T lymphocyte 17 20–25 .”
BackgroundLe microbiote, un nouvel acteur dans le diagnostic de la maladie d’Alzheimer
Girodon, L., & Hauet, P. (2025) · médecine/sciences · doi:10.1051/medsci/2025019 · Cited by 2
The role and significance of the oncobiota in selected cancers: a review
Walczak, Ł. J., Kosikowska, U., & Herbet, M. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01598-y · Cited by 1
“The composition of the gut microbiota varies according to several factors, including gender, comorbidities, diet, cancer type, and others [9–12].”
Introduction to Gut Microbiota and Its Role in Health and Diseases
Sharma, S., Hussain, M. S., Khan, Y., & Maqbool, M. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-86065-2_2 · Cited by 1
Mediators between gut microbiota and Alzheimer's disease: A mediation Mendelian randomization study
Dong, X., Han, Y., Wang, T.-B., Han, Y., & Liu, L. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251401157 · Cited by 1
Gu, S., Yin, W., Xie, M., He, C., Bian, Y., Li, L., Lu, W., & Wang, Q. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.02.003 · Cited by 1
Waghmare, A., Rahangdale, S. R., Khare, K., Taksande, B. G., Umekar, M. J., & Mangrulkar, S. V. (2026) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2026.104075 · Cited by 2
Xian, X., Chen, Z., Zhang, Y., Qi, J., Fan, H., Zeng, L., Bi, S., & Shen, K. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113172 · Cited by 1
Ni, Z., Xie, J., Zhang, Z., Zhang, K., Ding, J., Chang, M., Su, Y., Zhang, Y., Yao, M., Wang, C., et al. (2026) · iMeta · doi:10.1002/imt2.70148 · Cited by 2
Management of Huntington’s Disease by Faecal Microbiota Transplant (FMT) Technology
Pushkala, K., & Gupta, P. (2023) · doi:10.61440/jidt.2023.v1.04 · Cited by 1
Importance of gut microbiome in Alzheimer's disease
Wojtania, M. A., Majewska, E. M., & Duda, W. (2024) · Environmental Medicine · doi:10.26444/ms/188315 · Cited by 1
РОЛЬ И ОСОБЕННОСТИ МИКРОБИОТЫ КИШЕЧНИКА ПРИ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
Турсуметова, Д. Р., Хан, Ю., Ткачёва, Л. В., & Раевский, К. П. (2024) · Успехи геронтологии · doi:10.34922/ae.2024.37.4.016 · Cited by 1
The microbiome: what a neurologist needs to know
Dehghanizai, A. B., Stewart, C. J., & Thomas, R. H. (2025) · Practical Neurology · doi:10.1136/pn-2024-004400 · Cited by 1
“68 72 The importance of gut microbiota in Alzheimer’s disease is still poorly understood.”
Identificación de circRNAs como biomarcadores epigenéticos candidatos en la enfermedad de Alzheimer
Urdánoz‐Casado, A. (2022) · Academica-e (Universidad Pública de Navarra) · doi:10.48035/tesis/2454/43427
Grabrucker, S., Marizzoni, M., Silajdžić, E., Lopizzo, N., Mombelli, E., Nicolas, S., Dohm-Hansen, S., Scassellati, C., Moretti, D. V., Rosa, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2272240/v1
Piana, G. S., Batista, C. D. C. L., Contão, H. D. O., Lopes, K. A., Silva, L. T. D., Cardoso, T. C., de Assunção, G. N., ZAMPROGNO, S. B., Cavalcante, R. L. D. C., Borges, S. R. A., et al. (2022) · International Journal of Health Science · doi:10.22533/at.ed.159312301013
Metadata
- Authors
- Varesi, A., Pierella, E., Romeo, M., Piccini, G. B., Alfano, C., Bjørklund, G., Oppong, A., Ricevuti, G., Esposito, C., Chirumbolo, S., & Pascale, A.
- Affiliations
- University of Pavia (IT)
- University of Lancashire (GB)
- Université Libre de Bruxelles (BE)
- Policlinico San Matteo Fondazione (IT)
- Council for Nutritional and Environmental Medicine (NO)
- University of Verona (IT)
- Corresponding author
- Varesi, Angelica
- Ricevuti, Giovanni
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2022-02-05
- Volume
- 14
- Issue
- 3
- Pages
- 668
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC8840394
- OpenAlex
- W4210475085
- Cited by
- 225
- References
- 248
- Citations by year
- 2026: 24 · 2025: 54 · 2024: 68 · 2023: 53 · 2022: 26
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CLOK (University of Central Lancashire) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Funders
- Università degli Studi di Pavia
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- gut microbiota, Alzheimer's disease, gut-brain axis, dysbiosis, neurodegeneration, microbiota-based therapy, prebiotics, probiotics, fecal microbiota transplantation, diet, early diagnosis, disease progression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Alzheimer Disease, Humans, Prebiotics, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.